期刊文献+

肾癌组织中HMGB1、MMP9的表达与临床分期、预后的相关性研究 被引量:10

Expressions of HMGB1 and MMP9 and their clinical significance in renal carcinoma
下载PDF
导出
摘要 目的探讨高迁移率族蛋白B1(HMGB1)、基质金属蛋白酶9(MMP9)在肾癌组织中的表达,及与肾癌临床病理特征、预后的相关性。方法采用免疫组织化学、实时定量聚合酶链反应法,检测67例肾透明细胞癌患者癌组织、癌旁组织中HMGB1、MMP9的表达,采用Person法分析其与临床病理学特征的相关性,采用Kaplan-Meier方法进行生存曲线分析,采用Cox比例风险模型分析影响患者预后相关因素。结果肾癌组织中HMGB1、MMP9表达高于癌旁肾组织,差异有统计学意义;肾癌肿瘤TNM分期、淋巴结转移度、肿瘤直径与HMGB1、MMP9表达相关,而不同性别、年龄间HMGB1、MMP9的表达差异无统计学意义;HMGB1、MMP9低表达肾癌患者的生存期要高于中、高表达患者,HMGB1、MMP9的表达水平与预后呈负相关;HMGB1、MMP9、肿瘤TNM分期、淋巴结转移度是影响肾癌患者预后的独立危险因素。结论 HMGB1、MMP9可能在肾癌的浸润、转移机制中起着非常重要的作用,联合检测肾癌组织中HMGB1和MMP9的表达水平可能有助于评估肾癌的生物学特征和患者预后。 Objective To investigate the expressions of high mobility group box 1 protein (HMGB1) and matrix metalloproteinase 9 (MMP9) in renal carcinoma tissue and their relationship with clinic pathological characteristics of renal carcinoma. Methods The expressions of HMGB1 and MMP9 in 67 patients with renal carcinoma were determined using real-time PCR and immunohistochemistry. Statistical analysis was then conducted using Person, Kaplan-Meier and Cox proportional hazards analyses. Results The expressions of HMGB1 and MMP9 in the carcinoma tissues were higher than those in the para-carcinoma tissues, and closely related to TNM stage, lymph node ratio and diameter of tumor. The life time of the patients with low expressions of HMGB1 and MMP9 was longer than the patients with high expressions. The expressions of HMGB1 and MMP9 were negatively correlated with the prognosis. HMGB1, MMP9, TNM stage and lymph node metastasis were independent risk factors for the prognosis of renal carcinoma. Conclusions HMGB1 and MMP9 may play crucial roles in the infiltration and metastasis of renal carcinoma. Joint detection of HMGB1 and MMP9 in renal carcinoma tissues may help to evaluate the prognosis of patients.
出处 《中国现代医学杂志》 CAS 北大核心 2016年第22期28-33,共6页 China Journal of Modern Medicine
关键词 肾癌 HMGB1 MMP9 预后 renal carcinoma high mobility group box 1 protein matrix metalloproteinase 9 prognosis
  • 相关文献

参考文献3

二级参考文献53

  • 1JEMAL A, SIEGEL R, WARD E, et al. Cancer statistics2009 [J]. CA Cancer J Clin, 2009,59(4): 225-249.
  • 2KUME H, KAKUTANI S, Y YAMADA, et al. Prognostic fac- tors for renal cell carcinoma with bone metastasis: who are the long-term survivors? [J]. J Urol, 2011,185(5) : 1611-1614.
  • 3MUSTAFA A, GUPTA S, HUDES GR, et al. Serum amino acid levels as a biomarker for renal cell carcinoma [J]. J Urol, 2011, 186(4): 1206-1212.
  • 4CHEVILLE JC, LOHSE CM, ZINCKE H, et aI. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma[J]. Am J Surg Pathol, 2003, 27(5): 612- 624.
  • 5WHITE NM, YOUSEF GM. Translating molecular signatures of renal cell carcinoma into clinical practice[J]. J Urol, 2011, 186(1) : 9-11.
  • 6DIAMANDIS M, WHITE NM, YOUSEF GM. Personalized medicine: marking a new epoch in cancer patient management [J]. MolCancerRes, 2010,8(9): 1175-1187.
  • 7WHITE NM, FATOOHI E, METIAS M, et al. Metastamirs:a stepping stone towards improved cancer management[J]. Nat Rev Clin Oncol, 2011,8(2) :75-84.
  • 8ROMASCHIN AD, YOUSSEF Y,CHOW TF, et al. Exploring the pathogenesis of renal cell eareinoma: pathway and bioinfor- matics analysis of dysregulated genes and proteins [ J]. Biol Chem, 2009,390(2) : 125-135.
  • 9JOHNSON TV, S ALI, A ABBASI, et aL intratumor C-reac- tive protein as a biomarker of prognosis in localized renal cell car- cinoma[J]. J Uro], 2011,186(4): 1213-1217.
  • 10SANJMYATAV J, STEINER T, WUNDERLICH H, et al. A specific gene expression signature characterizes metastatic poten- tial in clear cell renal cell carcinoma[J]. J Urol, 2011,186(1I) 289-294.

共引文献21

同被引文献62

引证文献10

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部